Her-2阳性乳腺癌靶向治疗药物的研究进展

Research Progress in Treatment of Her-2-Positive Breast Cancer with Targeted Agents

Her-2阳性乳腺癌患者预后较差。近年来化疗序贯曲妥珠单抗1年的辅助治疗已成为早期Her-2阳性乳腺癌患者的标准治疗方案,曲妥珠单抗的应用使乳腺癌患者的复发风险降低了40%,然而长期随访数据表明,15%~24%患者仍面临复发风险。后续抗Her-2药物的研制主要集中在预防和克服耐药性方面,帕妥珠单抗、拉帕替尼、T-DM1、来那替尼和吡咯替尼等药物研发改善了Her-2阳性乳腺癌患者的辅助治疗空间。

Breast cancer with Her-2 + phenotype indicates an unfavorable prognosis for patients.Over the past years,the adjuvant therapy with chemotherapy plus 1-year administration of trastuzumab has become a standard treatment for early-stage Her-2+ breast cancer patients,which reduced the risk of relapse by 40%. However,long-term follow-up data show that 15% to 24% of patients still face the risk of recurrence. The newly emerging anti-Her-2 agents such as pertuzumab,lapatinib,T-DM1,neratinib and pyrotinib,mainly focusing on the prevention and overcome of drug resistance,have improved the efficacy of adjuvant therapy for Her-2+ breast cancer patients.